证券之星消息，截至2025年8月20日收盘，通策医疗(600763)报收于46.41元，上涨1.31%，换手率 2.34%，成交量10.49万手，成交额4.84亿元。 8月20日的资金流向数据方面，主力资金净流入2909.43万元，占总成交额6.01%，游资资金净流出 726.79万元，占总成交额1.5%，散户资金净流出2182.63万元，占总成交额4.51%。 近5日资金流向一览见下表： | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-20 | 46.41 1.31% | 2909.43万 | 6.01% | -726.79万 | -1.50% | -2182.63万 | -4.51% | | 2025-08-19 | 45.81 -0.80% | -5323.34万 | -10.04% | 2071.69万 | 3.91% | 3251.65万 | 6.13% | | 2025-08-18 | 46.18 2.26% ...

Company Overview - Tongce Medical's closing price on August 20 was 46.41 yuan, with an increase of 1.31%, resulting in a rolling PE ratio of 40.53, the lowest in 16 days, and a total market value of 20.759 billion yuan [1] - The company's main business includes providing oral medical services and research, with key products being medical services, product sales, construction engineering, and comprehensive service fees [1] Financial Performance - For the first quarter of 2025, Tongce Medical reported operating revenue of 745 million yuan, a year-on-year increase of 5.11%, and a net profit of 184 million yuan, up 6.22%, with a gross profit margin of 44.21% [1] Industry Comparison - The average PE ratio for the medical services industry is 49.21, with a median of 65.65, placing Tongce Medical at the 25th position within the industry [1] - The company has a total market value of 20.759 billion yuan, compared to the industry average market value of 20.077 billion yuan and the median of 71.97 billion yuan [2]

Market Overview - On August 20, the medical services sector rose by 0.33% compared to the previous trading day, with Haocen Medical leading the gains [1] - The Shanghai Composite Index closed at 3766.21, up 1.04%, while the Shenzhen Component Index closed at 11926.74, up 0.89% [1] Top Gainers in Medical Services - Haocen Medical (002622) closed at 3.96, up 10.00% with a trading volume of 827,000 shares and a transaction value of 322 million yuan [1] - Meinian Health (002044) closed at 5.87, up 4.45% with a trading volume of 2,284,200 shares and a transaction value of 1.323 billion yuan [1] - Baicheng Pharmaceutical (301096) closed at 56.47, up 3.31% with a trading volume of 72,900 shares and a transaction value of 401 million yuan [1] Top Losers in Medical Services - Innovation Medical (002173) closed at 23.05, down 7.21% with a trading volume of 1,255,900 shares and a transaction value of 2.968 billion yuan [2] - Boji Pharmaceutical (300404) closed at 12.36, down 6.01% with a trading volume of 819,000 shares and a transaction value of 1.015 billion yuan [2] - Nanmo Biological (688265) closed at 61.50, down 5.38% with a trading volume of 32,800 shares and a transaction value of 201 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 2.075 billion yuan from institutional investors, while retail investors saw a net inflow of 1.893 billion yuan [2][3] - The top net inflow from retail investors was in Meinian Health (002044) with 201 million yuan, despite a net outflow from institutional investors [3] - Haocen Medical (002622) had a net inflow of 114 million yuan from institutional investors, but also faced significant outflows from retail investors [3]

融券方面，当日融券卖出0.56万股，净卖出0.31万股。 来源：金融界 最近三个交易日，14日-18日，通策医疗分别获融资买入0.73亿元、0.68亿元、1.01亿元。 8月18日，沪深两融数据显示，通策医疗获融资买入额1.01亿元，居两市第352位，当日融资偿还额1.05 亿元，净卖出349.45万元。 ...

Group 1 - The core viewpoint of the news is that Tongce Medical (600763) has shown a slight increase in stock price and has reported positive financial performance for the first quarter of 2025, indicating growth in revenue and net profit [1][3]. Group 2 - As of August 15, 2025, Tongce Medical's stock closed at 45.16 yuan, up 0.38%, with a trading volume of 10.11 million shares and a transaction amount of 4.55 billion yuan [1]. - The company experienced a net outflow of main funds amounting to 27.87 million yuan, which accounted for 6.13% of the transaction amount [1]. - The latest financial report for the first quarter of 2025 shows total revenue of 745 million yuan, a year-on-year increase of 5.11%, and a net profit attributable to shareholders of 184 million yuan, up 6.22% year-on-year [1]. - The company's current ratio is 1.605, quick ratio is 1.556, and debt-to-asset ratio is 26.97% [1]. Group 3 - Tongce Medical has made investments in 12 companies and participated in 19 bidding projects, along with holding 11 administrative licenses [2].

Company Overview - Tongce Medical closed at 44.99 yuan, down 2.09%, with a rolling PE ratio of 39.29 times and a total market value of 20.124 billion yuan [1] - The company specializes in dental medical services and research, with main products including medical services, product sales, construction engineering, and comprehensive service fees [1] Financial Performance - For Q1 2025, Tongce Medical reported operating revenue of 745 million yuan, a year-on-year increase of 5.11%, and a net profit of 184 million yuan, up 6.22%, with a gross profit margin of 44.21% [1] Industry Comparison - The average PE ratio for the medical services industry is 49.00 times, with a median of 62.63 times, placing Tongce Medical at 24th in the industry ranking [1][2] - The total market value of the industry averages 20.418 billion yuan, with the median at 70.65 billion yuan [2] Institutional Holdings - As of Q1 2025, 16 institutions hold shares in Tongce Medical, all being funds, with a total holding of 11.4144 million shares valued at 471 million yuan [1]

金融界消息 截至2025年8月13日收盘，通策医疗（600763）报收于45.95元，上涨0.5%，换手率2.15%， 成交量9.64万手，成交金额4.43亿元。 天眼查商业履历信息显示，通策医疗股份有限公司，成立于1995年，位于杭州市，是一家以从事卫生为 主的企业。企业注册资本44728.9117万人民币，实缴资本32064万人民币。公司法定代表人为王毅。 通过天眼查大数据分析，通策医疗股份有限公司共对外投资了12家企业，参与招投标项目19次，此外企 业还拥有行政许可11个。 来源：金融界 资金流向方面，今日主力资金净流出1313.90万元，占比成交额2.96%。其中，超大单净流出1188.07万 元、占成交额2.68%，大单净流出125.83万元、占成交额0.28%，中单净流出流入201.56万元、占成交额 0.45%，小单净流入1112.34万元、占成交额2.51%。 通策医疗最新一期业绩显示，截至2025一季报，公司营业总收入7.45亿元、同比增长5.11%，归属净利 润1.84亿元，同比增长6.22%，扣非净利润1.82亿元，同比增长7.08%，流动比率1.605、速动比率 1.556、资产负债率 ...

Group 1 - The Ministry of Finance, People's Bank of China, and the Financial Regulatory Administration have issued a policy for personal consumption loan interest subsidies, covering loans below 50,000 yuan and key consumption areas such as automobiles, healthcare, and education [1] - Following the implementation of the personal consumption loan subsidy policy, banks like Agricultural Bank of China and Industrial and Commercial Bank of China have expressed intentions to promote the policy [1] - In Sichuan Province, the implementation of the consumption loan subsidy policy since 2023 has led to an increase in the growth rate of household consumption loans from 7.2% to 8.1%, indicating an improvement in consumer spending on automobiles and home appliances [1] Group 2 - Tongce Medical aims to expand its dental service area to over 260,000 square meters by the end of 2024, with 3,100 dental chairs and an expected outpatient volume of 3.5334 million [1] - Aier Eye Hospital is projected to have 352 hospitals and 229 outpatient departments by the end of December 2024, with a year-on-year increase of 12.1% in outpatient volume and 9.4% in surgical volume [1]

通过天眼查大数据分析，通策医疗股份有限公司共对外投资了12家企业，参与招投标项目19次，此外企 业还拥有行政许可11个。 通策医疗最新一期业绩显示，截至2025一季报，公司营业总收入7.45亿元、同比增长5.11%，归属净利 润1.84亿元，同比增长6.22%，扣非净利润1.82亿元，同比增长7.08%，流动比率1.605、速动比率 1.556、资产负债率26.97%。 天眼查商业履历信息显示，通策医疗股份有限公司，成立于1995年，位于杭州市，是一家以从事卫生为 主的企业。企业注册资本44728.9117万人民币，实缴资本32064万人民币。公司法定代表人为王毅。 金融界消息 截至2025年8月12日收盘，通策医疗（600763）报收于45.72元，下跌0.82%，换手率1.9%， 成交量8.50万手，成交金额3.90亿元。 资金流向方面，今日主力资金净流出2488.38万元，占比成交额6.38%。其中，超大单净流出418.64万 元、占成交额1.07%，大单净流出2069.75万元、占成交额5.31%，中单净流出流入2070.64万元、占成交 额5.31%，小单净流入417.74万元、占成交额1.07%。 ...

8月11日，沪深两融数据显示，通策医疗获融资买入额0.68亿元，居两市第306位，当日融资偿还额0.75 亿元，净卖出760.58万元。 最近三个交易日，7日-11日，通策医疗分别获融资买入0.75亿元、0.63亿元、0.68亿元。 融券方面，当日融券卖出0.94万股，净卖出0.88万股。 来源：金融界 ...